CYTO (altamiratherapeutics.com) Rega marang bathi mangsa ngarep
Altamira Therapeutics (CYTO) owns an active substance delivery platform, enabling the company to scale its business through royalties. The company's forward P/E ratio confirms this potential, with 0.00 indicating the level of this metric. The development of nasal sprays for RNA therapy expands patient reach for ENT pathologies, while an organic technology licensing strategy for big pharma behemoths establishes a foundation for long-term growth.
Ringkesan rincian data analitis Auris Medical (CYTO)
- rega saiki lan proyeksi nilai saham:
- indikator valuasi pasar bisnis:
- data ekuitas miturut neraca:
- data tingkat utang lan likuiditas finansial:
Total Utang marang Modal Altamira Therapeutics|CYTO - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Altamira Therapeutics|CYTO - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku Altamira Therapeutics Ltd|CYTO - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Altamira Therapeutics|Indikator likuiditas cepet altamiratherapeutics.com
- rincian asil keuangan lan kelipatan valuasi:
CYTO - Bathi sawise mbayar pajeg|Proyeksi bathi mangsa ngarep Altamira Therapeutics|CYTO - Pangali P/E|Rega marang bathi mangsa ngarep Altamira Therapeutics|CYTO - Pangali rega marang bathi tumrap wutah|Pangali EV/EBITDA Altamira Therapeutics Ltd|CYTO - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Altamira Therapeutics|CYTO - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan altamiratherapeutics.com|CYTO - Wutah bathi ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Altamira Therapeutics
Pambiji fundamental:Altamira Therapeutics Ltd.
For the intranasal RNA drug venture ecosystem of Altamira Therapeutics (CYTO), the company's forward P/E ratio serves as a gauge of market optimism regarding the future monetization of clinical trials. By dividing market capitalization by expected annual earnings, this chart assesses investors' willingness to pay a premium for the potential success of the sprays, while high volatility in the metric signals risks associated with stringent regulatory control over system toxicity.
Analisis perusahaan pesaing
Prakiraan rega marang bathi HLN (Haleon)|KVUE (Kenvue Inc) - Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Verona Pharma Corp VRNA|Jyong Bio (MENS) - Rasio prakiraan rega marang bathi|LGND: Prakiraan rega marang bathi|amneal.com - Rasio kapitalisasi marang bathi mangsa ngarep|PRGO: Pangali Forward P/E|Alvotech S.A. - Pangali mangsa ngarep rega marang bathi|LQDA (Liquidia Technologies) - Pangali Forward P/E|Rasio prakiraan rega marang bathi Galapagos Corp GLPG|Rega marang bathi mangsa ngarep ANI Pharmaceuticals (ANIP)|MNKD (mannkindcorp.com) - Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E AMPH (Amphastar Pharmaceuticals, Inc.)|Pangali Forward P/E Pacira Pharmaceuticals PCRX|SPRY - Rega marang bathi mangsa ngarep|TBPH: Rega marang bathi mangsa ngarep|AQST (Aquestive Therapeutics) - Prakiraan rega marang bathi|SCPH: Rasio kapitalisasi marang bathi mangsa ngarep|TECX (Tectonic Therapeutic Inc.) - Pangali Forward P/E|Pangali Forward P/E Tonix Pharma|Rega marang bathi mangsa ngarep China SXT Pharmaceuticals (SXTC)|Prakiraan rega marang bathi eupraxiapharma.com EPRX|Pangali Forward P/E BHST (BioHarvest Sciences)|Kapitalisasi marang proyeksi bathi invizyne.com (EXOZ)|ORMP - Rega marang bathi mangsa ngarep|Pangali mangsa ngarep rega marang bathi ENTX (Entera Bio Ltd.)|HYFT: Pangali Forward P/E|ABVC BioPharma, Inc (ABVC) - Pangali Forward P/E|Prakiraan rega marang bathi CPIX|QNTM: Pangali mangsa ngarep rega marang bathi|Prakiraan rega marang bathi FGEN (FibroGen)|Rasio kapitalisasi marang bathi mangsa ngarep TELO|Pangali Forward P/E RANI (Rani Therapeutics Holdings, Inc.)|Pangali mangsa ngarep rega marang bathi SNYR|Rallybio Corp. - Pangali Forward P/E|Rasio prakiraan rega marang bathi Lexaria Bioscience|Pulmatrix (PULM) - Rega marang bathi mangsa ngarep|Pheton Holdings - Pangali mangsa ngarep rega marang bathi|APM (Aptorum Group Ltd) - Pangali Forward P/E|Pangali Forward P/E Lyra Therapeutics Inc|Rega marang bathi mangsa ngarep Impact BioMedical Inc (IBO)|TNFA: Rasio rega marang bathi sing dikarepake|Pangali Forward P/E YCBD (cbdMD)|PainReform Ltd (PRFX) - Rasio prakiraan rega marang bathi|LIPO: Prakiraan rega marang bathi|OPTN - Pangali Forward P/E|PIRS (Pieris Pharmaceuticals) - Prakiraan rega marang bathi|PROC: Rasio kapitalisasi marang bathi mangsa ngarep|PTPI (Petros Pharmaceuticals, Inc.) - Pangali Forward P/E|Qilian International Holding Group (QLI) - Kapitalisasi marang proyeksi bathi|Pangali Forward P/E SLRN|Prakiraan rega marang bathi TFF Pharmaceuticals, Inc TFFP
